Objectives To estimate the prevalence of, and describe risk factors for, genital warts (GWs) in
the British population, following the introduction of the bivalent (human papillomavirus (HPV) …

Background Australia has provided free quadrivalent human papillomavirus (HPV) vaccines
to school girls since mid-2007 and a catch-up programme in the community to women aged …

Background Australia provided free quadrivalent human papillomavirus vaccines to 12–18-
year-old girls and women aged≤ 26 years from mid-2007 until the end of 2009. After this …

Background For several decades, diagnoses of genital warts at genitourinary medicine
(GUM) clinics in England had been increasing. In 2008, a national human papillomavirus …

Objective: This study aimed to determine if the Australian human papillomavirus (HPV)
vaccination programme has had a population impact on presentations of genital warts …

Objectives To estimate the total number of cases of, and cost of care for, genital warts (GWs)
in England, to inform economic evaluations of human papillomavirus vaccination. Methods …

Background. More than 90% of genital warts (GW) cases are caused by human
papillomavirus (HPV) types 6 and 11. The introduction of HPV vaccines necessitates the …

Objective. To asses the burden and correlates of genital warts in women. Methods. We
conducted a population-based cross-sectional study in 69,147 women (18–45 years of age) …

In this Review, we describe the recent epidemiology of genital warts and postulate what the
future may hold as a result of the introduction of the quadrivalent human papillomavirus …

Background Approximately 90% of genital warts (GWs) are caused by human
papillomavirus (HPV) types 6 and 11. Denmark has provided the quadrivalent HPV vaccine …